Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Yonsei University
Age
20–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Older than 20 years old and younger than 80 years old
Pathologically confirmed pancreatic ductal adenocarcinoma (metastatic or locally advanced stage)
ECOG Performance status ≤2
Scheduled fot concurrent chemoradiation
Adequate liver function (total bilirubin \< 1.5 X the upper limits of normal (ULN), AST and ALT \<3 X UNL, and alkaline phosphatases \< 3 X ULN or \< 5 x ULN in case of liver involvement)
Not remarkable coagulation profile (PT \< 1.5 international normalized ratio(INR), aPTT \<35 sec)
Subjects who given written informed consent after being given a full description of the study
You may not be if
Coexisting of other malignancies within 5 years, except squamous cell carcinoma and basal cell carcinoma of the skin
Evidence of distant metastasis, such as liver, peritoneum and brain
history of receiving the chemoradiation for pancreatic cancer in the other hospital
History of receiving the operation which affect the anatomy of upper gastrointestinal tract
Any trouble for examination of upper endoscopy
Evidence of GI ulcers (A1\~H2) on endoscopy before start of chemoradiotherapy.
Use of aspirin, anti-platelet agent, anticoagulation agent, NSAIDs, or glucocorticoid within 1 week or enable to stop the administration (including start during chemoradiation)
Use of PPI, Histamine-2 receptor antagonist, antacid, prostaglandin, sucralfate within 2 weeks or enable to stop the administration
Patients who are unwilling or unable to provide informed consent, such as those with psychiatric problem, drug abuse or alcoholism
Clareo Health | Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy
